期刊文献+

芦丁在正常及糖尿病肾病大鼠体内药代动力学研究 被引量:9

Pharmacokinetic study of rutin in normal and diabetic nephropathy rats
下载PDF
导出
摘要 目的比较芦丁在正常大鼠及糖尿病肾病大鼠体内药代动力学行为的差异。方法腹腔注射链脲霉素建立糖尿病肾病模型,静脉给予芦丁后取血分离血浆,采用HPLC-DAD法检测血浆中芦丁的浓度,以矩量法计算药代动力学参数。结果与正常大鼠比较,糖尿病肾病大鼠给予芦丁后体内AUC(0-4)明显增加〔(39.20±12.10)mg.h/L vs.(69.40±24.20)mg.h/L,P<0.01〕、体内平均滞留时间显著延长〔(0.726±0.13)h vs.(1.069±0.17)h,P<0.05〕、血浆消除半衰期显著增大〔(5.413±0.57)h vs.(6.595±0.38)h,P<0.05〕、血浆清除率显著减小〔(0.424±0.071)L.h-1.kg-1vs.(0.226±0.072)L.h-1.kg-1,P<0.05〕。结论芦丁在糖尿病肾病大鼠与正常大鼠之间存在明显的药代动力学差异。 Objective To investigate the difference in pharmacokinetic profiles of rutin in rats with diabetic nephropathy and normal ones. Methods The animal model of diabetic nephropathy was established by intraperitoneal injection (ip) of streptozotoein (STZ) in rats. Following intravenous administration of turin, blood samples were collected from the rats at the given time points to isolate plasma, which was assayed by HPLC - DAD method for the rutin concentration, and the pharmacokinetic parameters were analyzed by double - compartmental method (DAS2.0). Results The comparison between the pharmacokinetic parameters of normal rats and those of the rats with diabetic nephropathy showed that there was a marked increase in AUC(0-4) : (39.20 ± 12.10) mg · h/L vs. (69.40 ±24.20) mg · h/L (P 〈 0.01) ; prolonged mean retention time (MRT(0-4)) : (0.726 ±0.13) h vs. (1.069±0.17) h (P〈0.05) ; significant increase in elimination 1/2 life (t1/2) : (5.413 ±0.57) h vs. (6.595±0.38) h (P〈0.05) and markedly reduced plasma clearance ( Cl ) : ( 0.424 ± 0.071 ) L · h · kg^-1 vs. ( 0.226 ± 0.072 ) L · h · kg^-1 ( p 〈 0.05 ), respectively. Conclusion The results indicated that there were evident differences in pharmaeokinetic profiles of rutin between rats with diabetic nethropathy and normal ones.
出处 《徐州医学院学报》 CAS 2009年第11期708-712,共5页 Acta Academiae Medicinae Xuzhou
基金 江苏高校自然科学基金(07KJD360225)
关键词 芦丁 糖尿病肾病 药代动力学 大鼠 rutin diabetic nephropathy pharmacokinetic rat
  • 相关文献

参考文献11

  • 1Kuntic V, Pejic N, Ivkovic B, et al. Isocratic RP - HPLC method for rutin determination in solid oral dosage forms[J]. J Pharm Biomed Anal, 2007,43(2) :718 -721.
  • 2Nassiri- Asl M, Shariati -Rad S, Zamansoltani F. Anticonvulsive effects of intraeerebroventricular administration of rutin in rats [J]. Prog Neuro psychopharmacol Biol Psychiatry, 2008,32(4) : 989 - 993.
  • 3Alia M, Mateos R, Ramos S, et al. Influence of quercetln and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2) [ J]. Eur J Nutr, 2006,45 ( 1 ) : 19 - 28.
  • 4Kampkotter A, Nkwonkam CG, Zurawski RF, et al. Investigations of protective effects of the flavonoids quercetin and rutin on stress resistance in the model organism Caenorhabditis elegans [ J]. Toxicology, 2007,234 ( 1 -2) :113 - 123.
  • 5Cervantes- Laurean D, Schramm DD, Jacobson EL, et al. Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites [J]. J Nutr Biochem, 2006,17 (8) :531 - 540.
  • 6Kamalakkannan N, Stanely Mainzen Prince P. Rutin improves the antioxidant status in streptozotocin - induced diabetic rat tissues [J]. MolCellBiochem, 2006,293(1-2) : 211 -219.
  • 7Nagasawa T, Tabata N, ho Y, et al. Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative [ J]. Mol Cell Bioehem, 2003,249 ( 1 - 2) : 3 - 10.
  • 8Kim H, Kong H, Choi B, et al. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease [ J ]. Pharm Res, 2005,22 (9) : 1499 - 1509.
  • 9姜宝红,苏环德,徐峰,李京才.芦丁对糖尿病肾病的防治作用[J].黑龙江医学,2005,29(12):899-901. 被引量:13
  • 10肖小华.复方芦丁的药代动力学研究[J].局解手术学杂志,2004,13(6):367-369. 被引量:4

二级参考文献10

  • 1郑学钦,胡春.用化学发光法检测芦丁等物质清除超氧阴离子自由基的作用[J].中国药学杂志,1997,32(3):140-142. 被引量:31
  • 2Folts JD. Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin[J]. Int J Cardiol, 1997,62(Suppl 2):S111-117.
  • 3林启寿.中草药成份化学[M].北京:科学出版社,1997.343.
  • 4何高琴 张渝娟 周启新.MgCl2和ATP对犬离体冠脉条的协同解痉作用[J].中华心血管病杂志,1992,20(5):302-302.
  • 5Nathan D M.Long-term complications of diabetes mellitus[J].N Engl J Med,1993,328(23):1 676.
  • 6Higgins G.Hits and misses in treating diabetic complications:part Ⅰ[J].Inpharma,1996,(1 044):3.
  • 7Brownllee M.Nonenzymatic glycosylation and the pathogenesis of the diabetic complications[J].Ann Intern Med,1984,101:527.
  • 8Reynolds James E F.Martindale the extra pharmacopoeia[M].31st ed.London:Pharmaceutical Press,1996.342.
  • 9Kirchain W R.Aldose reductase inhititors[J].Pharmacotherapy,1990,10:326.
  • 10刘聪,刘润华,潘莉莉,李强,郭兑山.糖化LDL、氧化LDL与糖尿病血管病变的关系[J].中华内分泌代谢杂志,1998,14(1):52-52. 被引量:7

共引文献15

同被引文献135

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部